Genecast Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$4.76M
- Investors
-
13
Genecast General Information
Description
Developer of cancer diagnostic technology equipment designed to detect, diagnose and treat early-stage cancer. The company's technology amplifies only mutated genes while leaving the normal genes intact and its liquid biopsy method analyzes mutant tumor DNA in the blood, allowing cancer patients to be treated through a fast, accurate, and effective treatment.
Contact Information
Website
www.igenecast.comCorporate Office
- Office 10006, 10007 Garden 5 Techno Hall
- 66 Chungmin-ro, Songpa-gu
- Seoul
- South Korea
Corporate Office
- Office 10006, 10007 Garden 5 Techno Hall
- 66 Chungmin-ro, Songpa-gu
- Seoul
- South Korea
Genecast Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Later Stage VC (Series C) | 23-Feb-2023 | $4.76M | Completed | Generating Revenue | ||
3. Early Stage VC (Series B) | 08-Jun-2020 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 01-May-2018 | $4.85M | $4.85M | Completed | Startup | |
1. Seed Round | 01-Dec-2017 | Completed | Startup |
Genecast Patents
Genecast Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2020531044-A | Dna polymerizing enzyme with increased gene mutation specificity and pcr buffer composition for increasing its activity | Active | 12-Jul-2017 | ||
EP-3653729-A1 | Dna polymerase with increased gene mutation specificity and pcr buffer composition for increasing activity thereof | Pending | 12-Jul-2017 | ||
JP-6986299-B2 | Dna polymerizing enzyme with increased gene mutation specificity and pcr buffer composition for increasing its activity | Active | 12-Jul-2017 | ||
US-20200149018-A1 | Dna polymerase with increased gene mutation specificty and pcr buffer composition for increasing activity thereof | Active | 12-Jul-2017 | ||
EP-3653729-A4 | Dna polymerase with increased gene mutation specificity and pcr buffer composition for increasing activity thereof | Pending | 12-Jul-2017 | C12N9/1252 |
Genecast Signals
Genecast Investors (13)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Access Bio | Corporation | Minority | ||
DK&D | Corporation | Minority | ||
GC Biopharma | Corporation | Minority | ||
GC Medis | Venture Capital | Minority | ||
KB Investment | Venture Capital | Minority |
Genecast FAQs
-
When was Genecast founded?
Genecast was founded in 2016.
-
Where is Genecast headquartered?
Genecast is headquartered in Seoul, South Korea.
-
What is the size of Genecast?
Genecast has 29 total employees.
-
What industry is Genecast in?
Genecast’s primary industry is Diagnostic Equipment.
-
Is Genecast a private or public company?
Genecast is a Private company.
-
What is Genecast’s current revenue?
The current revenue for Genecast is
. -
How much funding has Genecast raised over time?
Genecast has raised $21.3M.
-
Who are Genecast’s investors?
Access Bio, DK&D, GC Biopharma, GC Medis, and KB Investment are 5 of 13 investors who have invested in Genecast.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »